Loading
FANCC (Fanconi anaemia group C protein) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Leukaemia, Pancreatic ductal adenocarcinoma and 5 more.
DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. Upon IFNG induction, may facilitate STAT1 activation by recruiting STAT1 to IFNGR1.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Gemcitabine, Mitomycin, Cisplatin and Chlorambucil and others. Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes genetic literature 0.85, affected pathway 0.76, literature 0.89, genetic association 0.68, somatic mutation 0.98).
In plain words · FANCC (Fanconi anaemia group C protein) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Leukaemia, Pancreatic ductal adenocarcinoma and 5 more.
FANCC (Fanconi anaemia group C protein) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Leukaemia, Pancreatic ductal adenocarcinoma and 5 more.
DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability.
No product in this corpus aims at FANCC yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Germline variant: UniProt lists Fanconi anemia complementation group C (FANCC) under involvement in disease, and the record is a DNA repair gene; the medicines linked to it act through the loss (synthetic lethality) or use the variant to pick patients. HPA FANCC: RNA tissue enhanced (liver 23 nTPM); blood lineage lineage enriched (granulocytes 11 nTPM); high antibody staining in 1 normal tissue; highest cancer staining glioma (1 of 12 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Leukaemia, Pancreatic ductal adenocarcinoma, Ovarian cancer, Colorectal cancer, Myeloid neoplasms); Open Targets associates it with 4 specific cancer types at or above 0.5 (hereditary neoplastic syndrome, acute myeloid leukemia, myelodysplastic syndrome, breast cancer). (Rule 2 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q00597; Human Protein Atlas FANCC tissue; Open Targets ENSG00000158169 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Strathdee C.A. et al, Nature, 1992, "Cloning of cDNAs for Fanconi's anaemia by functional complementation". Source.
Sources: HGNC HGNC:3584 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q00597 (protein name, function text, keywords and locations (REST API)); CIViC gene FANCC (1 evidence items, 0 assertions, 1 variants; diseases: Pancreatic Cancer (GraphQL API, CC0)); Open Targets ENSG00000158169 (association with cancer (MONDO_0004992) 0.80; per-cancer scores at or above 0.5: colorectal cancer 0.56, ovarian cancer 0.56, acute myeloid leukaemia 0.54, myelodysplastic syndrome 0.51, myeloproliferative neoplasm 0.54, breast cancer 0.65 (GraphQL API, CC0))
DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. Upon IFNG induction, may facilitate STAT1 activation by recruiting STAT1 to IFNGR1. Location: Nucleus; Cytoplasm (UniProt). Locus 9q22.32 (HGNC).
RNA: tissue enhanced (liver 23 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 11 nTPM).
Medium: Adrenal gland, Appendix, Bone marrow, Breast, Bronchus, Cerebellum, Cerebral cortex, Cervix.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FANCC" OR ABSTRACT:"FANCC" OR TITLE:"FA complementation group C" OR ABSTRACT:"FA complementation group C" OR TITLE:"Fanconi anemia group C protein" OR ABSTRACT:"Fanconi anemia group C protein" OR TITLE:"FA3" OR ABSTRACT:"FA3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FANCC, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Ovarian cancer.